| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Syndax Pharmaceuticals (NASDAQ:SNDX) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Syndax Pharmaceuticals to report an earnings per share (EPS) of $-0.72.
Investors in Syndax Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
In the previous earnings release, the company beat EPS by $0.17, leading to a 21.1% increase in the share price the following trading session.
Here's a look at Syndax Pharmaceuticals's past performance and the resulting price change:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| EPS Estimate | -1.00 | -1.27 | -1.08 | -1.11 |
| EPS Actual | -0.83 | -0.98 | -1.10 | -0.98 |
| Price Change % | 21.00 | -22.00 | -7.00 | 8.00 |
Shares of Syndax Pharmaceuticals were trading at $13.39 as of October 30. Over the last 52-week period, shares are down 27.09%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
To track all earnings releases for Syndax Pharmaceuticals visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: SNDX
